Leishmania donovani-induced prostaglandin E2 generation is critically dependent on host Toll-like receptor 2-cytosolic phospholipase A2 signaling

Infection and Immunity

Volumn 84, Issue 10, 2016, Pages 2963-2973

  Bhattacharjee, Amrita ^a   Majumder, Saikat ^a   Das, Shibali ^a   Ghosh, Sweta ^a   Biswas, Satabdi ^a   Majumdar, Subrata ^a  

^a BOSE INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CALCIUM; CALCIUM INDEPENDENT PHOSPHOLIPASE A2; CYCLOOXYGENASE 2; CYTOSOLIC PHOSPHOLIPASE A2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; PROSTAGLANDIN E2; PROTEIN; PROTEIN NFATC2; TOLL LIKE RECEPTOR 2; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CALCIUM CELL LEVEL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENETIC TRANSCRIPTION; LEISHMANIA DONOVANI; LEISHMANIASIS; MACROPHAGE; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; TRANSCRIPTION INITIATION; WESTERN BLOTTING; ANALYSIS OF VARIANCE; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; PHYSIOLOGY; VISCERAL LEISHMANIASIS;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MACROPHAGES; MICE; MICE, INBRED BALB C; PHOSPHOLIPASES A2, CYTOSOLIC; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2;

EID: 84994285737     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00528-16     Document Type: Article

References (47)

1. Ashkenazi A, Faingold O, Shai Y. 2013. HIV-1 fusion protein exerts complex immunosuppressive effects. Trends Biochem Sci 38:345-349. http://dx.doi.org/10.1016/j.tibs.2013.04.003.
2. Loeuillet C, Martinon F, Perez C, Munoz M, Thome M, Meylan PR. 2006 Mycobacterium tuberculosis subverts innate immunity to evade specific effectors. J Immunol 177:6245-6255. http://dx.doi.org/10.4049/jimmunol.177.9.6245.
3. Skorokhod OA, Alessio M, Mordmuller B, Arese P, Schwarzer E. 2004. Hemozoin (malarial pigment) inhibits differentiation and maturation of human monocyte-derived dendritic cells: a peroxisome proliferatoractivated receptor-gamma-mediated effect. J Immunol 173:4066-4074. http://dx.doi.org/10.4049/jimmunol.173.6.4066.
4. Olivier M, Gregory DJ, Forget G. 2005. Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view. Clin Microbiol Rev 18:293-305. http://dx.doi.org/10.1128/CMR.18.2.293-305.2005.
5. Plescia OJ, Smith AH, Grinwich K. 1975. Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci U S A 72: 1848-1851. http://dx.doi.org/10.1073/pnas.72.5.1848.
6. Harizi H, CorcuffJB, Gualde N. 2008. Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol Med 14: 461-469. http://dx.doi.org/10.1016/j.molmed.2008.08.005.
7. Nakanishi M, Rosenberg DW. 2013. Multifaceted roles of PGE2 in inflammation and cancer. Semin Immunopathol 35:123-137. http://dx.doi.org/10.1007/s00281-012-0342-8.
8. Kalinski P. 2012. Regulation of immune responses by prostaglandin E2. J Immunol 188:21-28. http://dx.doi.org/10.4049/jimmunol.1101029.
9. Serezani CH, Chung J, Ballinger MN, Moore BB, AronoffDM, Peters-Golden M. 2007. Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase. Am J Respir Cell Mol Biol 37:562-570. http://dx.doi.org/10.1165/rcmb.2007-0153OC.
10. Snijdewint FG, Kalinski P, Wierenga EA, Bos JD, Kapsenberg ML. 1993. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol 150:5321-5329.
11. Johansson C, Bergstrom S. 1982. Prostaglandin and protection of the gastroduodenal mucosa. Scand J Gastroenterol Suppl 77:21-46.
12. Yin H, Cheng L, Langenbach R, Ju C. 2007. Prostaglandin I(2) and E(2) mediate the protective effects of cyclooxygenase-2 in a mouse model of immune-mediated liver injury. Hepatology 45:159-169. http://dx.doi.org/10.1002/hep.21493.
13. Matte C, Maion G, Mourad W, Olivier M. 2001. Leishmania donovaniinduced macrophages cyclooxygenase-2 and prostaglandin E2 synthesis. Parasite Immunol 23:177-184. http://dx.doi.org/10.1046/j.1365-3024.2001.00372.x.
14. Saha A, Biswas A, Srivastav S, Mukherjee M, Das PK, Ukil A. 2014. Prostaglandin E2 negatively regulates the production of inflammatory cytokines/chemokines and IL-17 in visceral leishmaniasis. J Immunol 193: 2330-2339. http://dx.doi.org/10.4049/jimmunol.1400399.
15. Kaiser E, Chiba P, Zaky K. 1990. Phospholipases in biology and medicine. Clin Biochem 23:349-370. http://dx.doi.org/10.1016/0009-9120 (90)90051-U.
16. Marshall J, Krump E, Lindsay T, Downey G, Ford DA, Zhu P, Walker P, Rubin B. 2000. Involvement of cytosolic phospholipase A2 and secretory phospholipase A2 in arachidonic acid release from human neutrophils. J Immunol 164:2084-2091. http://dx.doi.org/10.4049/jimmunol.164.4.2084.
17. Bhattacharjee S, Bhattacharjee A, Majumder S, Majumdar SB, Majumdar S. 2012. Glycyrrhizic acid suppresses Cox-2-mediated antiinflammatory responses during Leishmania donovani infection. J Antimicrob Chemother 67:1905-1914. http://dx.doi.org/10.1093/jac/dks159.
18. Fahey TJ, Tracey KJ, Tekamp-Olson P. 1992. Macrophage inflammatory protein-1 modulates macrophage function. J Immunol 148:2764-2769.
19. Manzanero S. 2012. Generation of mouse bone marrow-derived macrophages. Methods Mol Biol 844:177-181. http://dx.doi.org/10.1007/978-1-61779-527-5_12.
20. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
21. Adhikari A, Majumder S, Banerjee S, Gupta G, Bhattacharya P, Majumdar SB, Saha B, Majumdar S. 2012. Mycobacterium indicus pranii (Mw)-mediated protection against visceral leishmaniasis: involvement of TLR4 signalling. J Antimicrob Chemother 67:2892-2902. http://dx.doi.org/10.1093/jac/dks315.
22. Roy N, Chakraborty S, Paul Chowdhury B, Banerjee S, Halder K, Majumder S, Majumdar S, Sen PC. 2014. Regulation of PKC mediated signaling by calcium during visceral leishmaniasis. PLoS One 9:e110843. http://dx.doi.org/10.1371/journal.pone.0110843.
23. Ghosh S, Bhattacharyya S, Sirkar M, Sa GS, Das T, Majumdar D, Roy S, Majumdar S. 2002. Leishmania donovani suppresses activator protein-1 and NF-kB in host macrophages via ceramide generation: involvement of extracellular signal regulated kinase. Infect Immun 70:6828-6838. http://dx.doi.org/10.1128/IAI.70.12.6828-6838.2002.
24. Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB. 1986. Arachidonic acid metabolism. Annu Rev Biochem 55:69-102. http://.dx.doi.org/10.1146/annurev.bi.55.070186.000441.
25. Six DA, Dennis EA. 2000. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim Biophys Acta 1488:1-19. http://dx.doi.org/10.1016/S1388-1981(00)00105-0.
26. Lindner SC, Kohl U, Maier TJ, Steinhilber D, Sorg BL. 2009. TLR2 ligands augment cPLA2alpha activity and lead to enhanced leukotriene release in human monocytes. J Leukoc Biol 86:389-399. http://dx.doi.org/10.1189/jlb.1008591.
27. Srivastava S, Pandey SP, Jha MK, Chandel HS, Saha B. 2013. Leishmania expressed lipophosphoglycan interacts with Toll-like receptor (TLR)-2 to decrease TLR-9 expression and reduce anti-leishmanial responses. Clin Exp Immunol 172:403-409. http://dx.doi.org/10.1111/cei.12074.
28. Ball A. 1999. Interfacial membrane docking of cytosolic phospholipase A2 C2 domain using electrostatic potential-modulated spin relaxation magnetic resonance. Proc Natl Acad Sci U S A 96:6637-6642.
29. Chun J, Prince A. 2009. Ca2+ signaling in airway epithelial cells facilitates leukocyte recruitment and transepithelial migration. J Leukoc Biol 86:1135-1144. http://dx.doi.org/10.1189/jlb.0209072.
30. Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A, Davis RJ. 1993. cPLA2 is phosphorylated and activated by MAP kinase. Cell 72:269-278. http://dx.doi.org/10.1016/0092-8674(93)90666-E.
31. Crabtree GR, Olson EN. 2002. NFAT signaling: choreographing the social lives of cells. Cell 109(Suppl):S67-S79. http://dx.doi.org/10.1016/S0092-8674(02)00699-2.
32. Abdalla GK, Faria GE, Silva KT, Castro EC, Reis MA, Michelin MA. 2008 Trypanosoma cruzi: the role of PGE2 in immune response during the acute phase of experimental infection. Exp Parasitol 118:514-521. http://dx.doi.org/10.1016/j.exppara.2007.11.003.
33. Chen JH, Perry CJ, Tsui YC, Staron MM, Parish IA, Dominguez CX, Rosenberg DW, Kaech SM. 2015. Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection. Nat Med 21:327-334. http://dx.doi.org/10.1038/nm.3831.
34. Goldmann O, Hertzen E, Hecht A, Schmidt H, Lehne S, Norrby-Teglund A, Medina E. 2010. Inducible cyclooxygenase released prostaglandin E2 modulates the severity of infection caused by Streptococcus pyogenes. J Immunol 185:2372-2381. http://dx.doi.org/10.4049/jimmunol.1000838.
35. Agard M, Asakrah S, Morici LA. 2013. PGE(2) suppression of innate immunity during mucosal bacterial infection. Front Cell Infect Microbiol 3:45. http://dx.doi.org/10.3389/fcimb.2013.00045.
36. Farrell JP, Kirkpatrick CE. 1987. Experimental cutaneous leishmaniasis. II. A possible role for prostaglandins in exacerbation of disease in Leishmania major-infected BALB/c mice. J Immunol 138:902-907.
37. Guimarães ET, Santos LA, Ribeiro dos Santos R, Teixeira MM, dos Santos WL, Soares MB. 2006. Role of interleukin-4 and prostaglandin E2 in Leishmania amazonensis infection of BALB/c mice. Microbes Infect 8:1219-1226. http://dx.doi.org/10.1016/j.micinf.2005.11.011.
38. Chandra D, Naik S. 2008. Leishmania donovani infection downregulates TLR2-stimulated IL-12p40 and activates IL-10 in cells of macrophage/monocytic lineage by modulating MAPK pathways through a contact-dependent mechanism. Clin Exp Immunol 154:224-234. http://dx.doi.org/10.1111/j.1365-2249.2008.03741.x.
39. Berridge MJ, Lipp P, Bootman MD. 2000. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 1:11-21. http://dx.doi.org/10.1038/35036035.
40. Burke JE, Dennis EA. 2009. Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 50(Suppl):S237-S42. http://dx.doi.org/10.1194/jlr. R800033-JLR200.
41. Bhattacharya P, Gupta G, Majumder S, Adhikari A, Banerjee S, Halder K, Majumdar SB, Ghosh M, Chaudhuri S, Roy S, Majumdar S. 2011. Arabinosylated lipoarabinomannan skews Th2 phenotype towards Th1 during Leishmania infection by chromatin modification: involvement of MAPK signaling. PLoS One 6:e24141. http://dx.doi.org/10.1371/journal.pone.0024141.
42. Mathur RK, Awasthi A, Wadhone P, Ramanamurthy B, Saha B. 2004. Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nat Med 10:540-544. http://dx.doi.org/10.1038/nm1045.
43. Kar P, Parekh AB. 2015. Distinct spatial Ca2+ signatures selectively activate different NFAT transcription factor isoforms. Mol Cell 58:232-243 http://dx.doi.org/10.1016/j.molcel.2015.02.027.
44. Xu L, Stevens J, Hilton MB, Seaman S, Conrads TP, Veenstra TD, Logsdon D, Morris H, Swing DA, Patel NL, Kalen J, Haines DC, Zudaire E, St Croix B. 2014. COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci Transl Med 6:242ra84. http://dx.doi.org/10.1126/scitranslmed.3008455.
45. Sharma-Walia N, Patel K, Chandran K, Marginean A, Bottero V, Kerur N, Paul AG. 2012. COX-2/PGE2: molecular ambassadors of Kaposi's sarcoma-associated herpes virus oncoprotein-v-FLIP. Oncogenesis 1:e5. http://dx.doi.org/10.1038/oncsis.2012.5.
46. Michalowski J. 2002. COX-2 inhibitors: cancer trials test new uses for pain drug. J Natl Cancer Inst 94:248-249. http://dx.doi.org/10.1093/jnci/94.4.248.
47. Bhattacharjee A, Majumder S, Majumdar SB, Choudhuri SK, Roy S, Majumdar S. 2015. Co-administration of glycyrrhizic acid with the antileishmanial drug sodium antimony gluconate (SAG) cures SAG-resistant visceral leishmaniasis. Int J Antimicrob Agents 45:268-277. http://dx.doi.org/10.1016/j.ijantimicag.2014.10.023.